MacroGenics (MGNX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

MGNX Stock Forecast


MacroGenics stock forecast is as follows: an average price target of $10.33 (represents a 221.81% upside from MGNX’s last price of $3.21) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.

MGNX Price Target


The average price target for MacroGenics (MGNX) is $10.33 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $4.00. This represents a potential 221.81% upside from MGNX's last price of $3.21.

MGNX Analyst Ratings


Hold

According to 10 Wall Street analysts, MacroGenics's rating consensus is 'Hold'. The analyst rating breakdown for MGNX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (40.00%), 6 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

MacroGenics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 07, 2024Stephen WilleyStifel Nicolaus$6.00$3.3877.51%86.92%
Jul 31, 2024Silvan TuerkcanJMP Securities$8.00$5.2552.38%149.22%
Jul 31, 2024Mayank MamtaniB.Riley Financial$5.00$5.25-4.76%55.76%
Jul 29, 2024Peter LawsonBarclays$9.00$5.5562.16%180.37%
May 23, 2024Kaveri PohlmanBTIG$9.00$4.6394.38%180.37%
May 13, 2024Debjit ChattopadhyayH.C. Wainwright$4.00$4.38-8.75%24.61%
May 10, 2024Peter LawsonBarclays$14.00$14.67-4.57%336.14%
May 10, 2024Etzer DaroutBMO Capital$8.00$14.67-45.47%149.22%
Apr 04, 2024Stephen WilleyStifel Nicolaus$29.00$13.67112.14%803.43%
Nov 22, 2022Charles ZhuGuggenheim$12.00$6.1894.17%273.83%
Row per page
Go to

The latest MacroGenics stock forecast, released on Aug 07, 2024 by Stephen Willey from Stifel Nicolaus, set a price target of $6.00, which represents a 77.51% increase from the stock price at the time of the forecast ($3.38), and a 86.92% increase from MGNX last price ($3.21).

MacroGenics Price Target by Period


1M3M12M
# Anlaysts--9
Avg Price Target--$10.22
Last Closing Price$3.21$3.21$3.21
Upside/Downside-100.00%-100.00%218.38%

In the current month, the average price target of MacroGenics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MacroGenics's last price of $3.21. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 18, 2024JMP SecuritiesMarket PerformMarket PerformHold
Sep 18, 2024H.C. WainwrightNeutralNeutralHold
Sep 16, 2024Cowen & Co.HoldHoldHold
Aug 21, 2024H.C. WainwrightNeutralNeutralHold
Aug 15, 2024JMP SecuritiesMarket PerformMarket PerformHold
Jul 31, 2024BTIGBuyNeutralDowngrade
Jul 31, 2024JMP SecuritiesOutperformOutperformHold
Jul 31, 2024GuggenheimAccumulateNeutralDowngrade
Jul 31, 2024B. Riley-NeutralDowngrade
Jul 31, 2024GuggenheimUnderperformAccumulateDowngrade
Row per page
Go to

MacroGenics's last stock rating was published by JMP Securities on Sep 18, 2024. The company gave MGNX a "Market Perform" rating, the same as its previous rate.

MacroGenics Financial Forecast


MacroGenics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$11.00M$10.40M$13.14M$24.21M$71.18M$41.73M$26.01M$10.67M$13.62M$15.58M$30.37M$16.88M$52.69M$18.25M$20.26M$13.68M$25.19M$18.74M$10.59M$9.66M$4.70M$2.06M
Avg Forecast$17.11M$24.21M$10.90M$11.93M$29.19M$87.61M$20.94M$14.86M$32.63M$50.90M$29.19M$96.19M$64.37M$29.28M$14.16M$23.18M$22.83M$34.01M$32.15M$26.20M$26.01M$14.04M$10.90M$9.48M$13.28M$15.26M$14.45M$18.80M$3.78M$1.85M
High Forecast$27.65M$39.12M$17.62M$18.30M$37.80M$87.71M$20.94M$24.01M$45.90M$51.73M$47.18M$155.43M$104.02M$29.28M$14.16M$23.18M$22.83M$34.01M$32.15M$26.20M$26.01M$14.04M$10.90M$9.48M$13.28M$15.26M$14.45M$18.80M$4.54M$2.21M
Low Forecast$7.92M$11.21M$5.05M$5.55M$18.19M$87.51M$20.94M$6.88M$18.36M$50.07M$13.52M$44.54M$29.81M$29.28M$14.16M$23.18M$22.83M$34.01M$32.15M$26.20M$26.01M$14.04M$10.90M$9.48M$13.28M$15.26M$14.45M$18.80M$3.03M$1.48M
# Analysts11136333633344443333101681171177178
Surprise %--------0.34%0.20%0.45%0.25%1.11%1.43%1.84%0.46%0.60%0.46%0.94%0.64%2.03%1.30%1.86%1.44%1.90%1.23%0.73%0.51%1.24%1.11%

MacroGenics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $14.86M, with a low forecast of $6.88M, and a high forecast of $24.01M. MGNX's average Quarter revenue forecast represents a 35.06% increase compared to the company's last Quarter revenue of $11.00M (Dec 23).

MacroGenics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11136333633344443333101681171177178
EBITDA--------$-151.71M$-35.50M$-44.96M$-37.35M$15.21M$-22.11M$-38.93M$-63.73M$-55.07M$-50.09M$-37.15M$-48.54M$803.00K$-33.08M$-43.59M$-41.91M$-27.67M$-41.99M$-29.19M$-42.11M$-48.20M$-35.68M
Avg Forecast$-12.58M$-17.80M$-8.01M$-8.77M$-21.46M$-64.41M$-15.39M$-41.33M$-23.99M$-37.42M$-21.46M$-44.21M$-57.62M$-28.11M$-13.59M$-47.28M$-21.91M$-32.65M$-30.86M$-28.01M$-24.96M$-13.48M$-10.47M$-46.44M$-12.75M$-14.65M$-13.87M$-35.75M$-36.59M$-31.63M
High Forecast$-5.83M$-8.24M$-3.71M$-4.08M$-13.37M$-64.33M$-15.39M$-33.07M$-13.50M$-36.81M$-9.94M$-35.36M$-46.10M$-28.11M$-13.59M$-37.82M$-21.91M$-32.65M$-30.86M$-22.41M$-24.96M$-13.48M$-10.47M$-37.15M$-12.75M$-14.65M$-13.87M$-28.60M$-29.28M$-25.30M
Low Forecast$-20.33M$-28.76M$-12.95M$-13.46M$-27.79M$-64.48M$-15.39M$-49.60M$-33.75M$-38.03M$-34.68M$-53.05M$-69.15M$-28.11M$-13.59M$-56.73M$-21.91M$-32.65M$-30.86M$-33.61M$-24.96M$-13.48M$-10.47M$-55.72M$-12.75M$-14.65M$-13.87M$-42.90M$-43.91M$-37.96M
Surprise %--------6.32%0.95%2.09%0.84%-0.26%0.79%2.86%1.35%2.51%1.53%1.20%1.73%-0.03%2.45%4.16%0.90%2.17%2.87%2.10%1.18%1.32%1.13%

3 analysts predict MGNX's average Quarter EBITDA for Mar 23 to be $-44.21M, with a high of $-35.36M and a low of $-53.05M. This is -390.56% lower than MacroGenics's previous annual EBITDA (Dec 22) of $15.21M.

MacroGenics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11136333633344443333101681171177178
Net Income--------$-45.83M$17.55M$57.47M$-38.25M$12.80M$-24.67M$-40.80M$-66.25M$-58.02M$-52.89M$-39.94M$-51.27M$-2.09M$-36.04M$-46.88M$-44.72M$-30.40M$-44.63M$-31.77M$-45.02M$-49.54M$-37.66M
Avg Forecast$-30.59M$-31.75M$-46.52M$-45.68M$-25.17M$13.30M$-41.55M$-43.23M$-9.65M$-5.99M$-32.76M$-46.23M$-60.71M$-24.04M$-61.34M$-49.45M$-51.06M$-44.52M$-28.54M$-29.59M$-45.66M$-58.32M$-57.65M$-49.55M$-64.02M$-62.27M$-60.70M$-38.21M$-37.61M$-33.38M
High Forecast$-9.24M$-9.59M$-14.05M$-34.26M$-7.66M$13.82M$-12.55M$-34.58M$-5.57M$-1.81M$-9.89M$-36.99M$-48.57M$-24.04M$-61.34M$-39.56M$-51.06M$-44.52M$-28.54M$-23.67M$-45.66M$-58.32M$-57.65M$-39.64M$-64.02M$-62.27M$-60.70M$-30.57M$-30.09M$-26.71M
Low Forecast$-55.09M$-57.17M$-83.77M$-57.10M$-45.96M$12.78M$-74.81M$-51.87M$-13.73M$-10.79M$-58.98M$-55.48M$-72.85M$-24.04M$-61.34M$-59.34M$-51.06M$-44.52M$-28.54M$-35.50M$-45.66M$-58.32M$-57.65M$-59.46M$-64.02M$-62.27M$-60.70M$-45.85M$-45.13M$-40.06M
Surprise %--------4.75%-2.93%-1.75%0.83%-0.21%1.03%0.67%1.34%1.14%1.19%1.40%1.73%0.05%0.62%0.81%0.90%0.47%0.72%0.52%1.18%1.32%1.13%

MacroGenics's average Quarter net income forecast for Dec 23 is $-9.65M, with a range of $-13.73M to $-5.57M. MGNX's average Quarter net income forecast represents a -154.96% decrease compared to the company's last Quarter net income of $17.55M (Sep 23).

MacroGenics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11136333633344443333101681171177178
SG&A--------$12.56M$12.41M$13.69M$13.53M$13.67M$15.36M$13.67M$16.25M$15.58M$17.16M$15.23M$15.04M$12.56M$9.73M$10.22M$10.23M$11.89M$11.83M$12.12M$10.22M$9.23M$7.46M
Avg Forecast$11.26M$15.93M$7.17M$7.85M$19.20M$57.63M$13.77M$10.57M$21.47M$33.48M$19.21M$11.31M$16.31M$19.26M$9.32M$12.10M$15.02M$22.38M$21.15M$8.68M$17.11M$9.24M$7.17M$6.24M$8.74M$10.04M$9.50M$8.67M$2.49M$1.21M
High Forecast$18.19M$25.74M$11.59M$12.04M$24.86M$57.70M$13.77M$12.69M$30.20M$34.03M$31.03M$13.57M$19.57M$19.26M$9.32M$14.51M$15.02M$22.38M$21.15M$10.41M$17.11M$9.24M$7.17M$6.24M$8.74M$10.04M$9.50M$10.41M$2.99M$1.46M
Low Forecast$5.21M$7.38M$3.32M$3.65M$11.97M$57.57M$13.77M$8.46M$12.08M$32.94M$8.89M$9.05M$13.04M$19.26M$9.32M$9.68M$15.02M$22.38M$21.15M$6.94M$17.11M$9.24M$7.17M$6.24M$8.74M$10.04M$9.50M$6.94M$1.99M$971.34K
Surprise %--------0.59%0.37%0.71%1.20%0.84%0.80%1.47%1.34%1.04%0.77%0.72%1.73%0.73%1.05%1.42%1.64%1.36%1.18%1.28%1.18%3.71%6.15%

MacroGenics's average Quarter SG&A projection for Mar 24 is $10.57M, based on 3 Wall Street analysts, with a range of $8.46M to $12.69M. The forecast indicates a -15.81% fall compared to MGNX last annual SG&A of $12.56M (Dec 23).

MacroGenics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11136333633344443333101681171177178
EPS--------$-0.00$0.28-$-0.62$-1.55$-0.40$-0.66$-1.08$-0.95$-0.86$-0.66$-0.90$-0.04$-0.66$-0.94$-0.91$-0.62$-0.91$-0.65$-0.99$-1.34$-1.08
Avg Forecast$-0.49$-0.51$-0.74$-0.73$-0.40$0.21$-0.66$-0.64$-0.15$-0.10$-0.52$0.45$0.10$-0.38$-0.98$-0.85$-0.81$-0.71$-0.46$-0.64$-0.73$-0.93$-0.92$-1.02$-1.02$-0.99$-0.97$-0.75$-0.82$-0.86
High Forecast$-0.15$-0.15$-0.22$-0.55$-0.12$0.22$-0.20$-0.19$-0.09$-0.03$-0.16$0.81$0.18$-0.38$-0.98$-0.85$-0.81$-0.71$-0.46$-0.64$-0.73$-0.93$-0.92$-1.02$-1.02$-0.99$-0.97$-0.75$-0.66$-0.69
Low Forecast$-0.88$-0.91$-1.33$-0.91$-0.73$0.20$-1.19$-1.16$-0.22$-0.17$-0.94$0.14$0.03$-0.38$-0.98$-0.85$-0.81$-0.71$-0.46$-0.64$-0.73$-0.93$-0.92$-1.02$-1.02$-0.99$-0.97$-0.75$-0.98$-1.03
Surprise %--------0.00%-2.94%-0.00%-1.37%-15.18%1.04%0.67%1.27%1.17%1.21%1.45%1.41%0.05%0.71%1.02%0.89%0.61%0.92%0.67%1.31%1.63%1.26%

According to 6 Wall Street analysts, MacroGenics's projected average Quarter EPS for Dec 23 is $-0.15, with a low estimate of $-0.22 and a high estimate of $-0.09. This represents a -154.81% decrease compared to MGNX previous annual EPS of $0.28 (Sep 23).

MacroGenics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IPSCCentury Therapeutics$1.24$15.001109.68%Buy
PMVPPMV Pharmaceuticals$1.61$18.001018.01%Buy
NGMNGM Biopharmaceuticals$1.54$16.50971.43%Buy
NKTXNkarta$2.44$21.60785.25%Buy
ANTXAN2 Therapeutics$1.23$8.75611.38%Buy
ZNTLZentalis Pharmaceuticals$3.18$21.86587.42%Buy
PEPGPepGen$4.32$29.50582.87%Buy
INZYInozyme Pharma$2.69$14.67445.35%Buy
MOLNMolecular Partners$5.42$29.00435.06%Buy
CCCCC4 Therapeutics$4.01$13.50236.66%Buy
MGNXMacroGenics$3.21$10.33221.81%Hold
DAWNDay One Biopharmaceuticals$13.34$38.80190.85%Buy
CGEMCullinan Oncology$12.22$31.50157.77%Buy
MLYSMineralys Therapeutics$11.87$30.00152.74%Buy
KZRKezar Life Sciences$7.62$17.50129.66%Buy
SNDXSyndax Pharmaceuticals$15.60$34.30119.87%Buy
TYRATyra Biosciences$15.36$31.75106.71%Buy
PHVSPharvaris$21.04$39.6788.55%Buy
EWTXEdgewise Therapeutics$31.98$45.0040.71%Buy
PTGXProtagonist Therapeutics$41.65$50.0020.05%Buy

MGNX Forecast FAQ


Is MacroGenics a good buy?

No, according to 10 Wall Street analysts, MacroGenics (MGNX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 40.00% of MGNX's total ratings.

What is MGNX's price target?

MacroGenics (MGNX) average price target is $10.33 with a range of $4 to $32, implying a 221.81% from its last price of $3.21. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will MacroGenics stock go up soon?

According to Wall Street analysts' prediction for MGNX stock, the company can go up by 221.81% (from the last price of $3.21 to the average price target of $10.33), up by 896.88% based on the highest stock price target, and up by 24.61% based on the lowest stock price target.

Can MacroGenics stock reach $5?

MGNX's average twelve months analyst stock price target of $10.33 supports the claim that MacroGenics can reach $5 in the near future.

What are MacroGenics's analysts' financial forecasts?

MacroGenics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $152.6M (high $170.46M, low $133.51M), average EBITDA is $-143M (high $-126M, low $-157M), average net income is $-96.643M (high $-40.972M, low $-160M), average SG&A $101.18M (high $109.03M, low $91.76M), and average EPS is $-1.492 (high $-0.296, low $-2.875). MGNX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.15M (high $102.69M, low $29.73M), average EBITDA is $-47.158M (high $-21.856M, low $-75.494M), average net income is $-155M (high $-67.138M, low $-253M), average SG&A $42.2M (high $67.55M, low $19.56M), and average EPS is $-2.458 (high $-1.068, low $-4.027).

Did the MGNX's actual financial results beat the analysts' financial forecasts?

Based on MacroGenics's last annual report (Dec 2023), the company's revenue was $58.75M, which missed the average analysts forecast of $208.91M by -71.88%. Apple's EBITDA was $-168M, beating the average prediction of $-127M by 32.40%. The company's net income was $-9.058M, missing the average estimation of $-94.626M by -90.43%. Apple's SG&A was $52.19M, missing the average forecast of $85.47M by -38.94%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.317 by -99.97%. In terms of the last quarterly report (Dec 2023), MacroGenics's revenue was $11M, missing the average analysts' forecast of $32.63M by -66.28%. The company's EBITDA was $-152M, beating the average prediction of $-23.99M by 532.38%. MacroGenics's net income was $-45.833M, beating the average estimation of $-9.648M by 375.05%. The company's SG&A was $12.56M, missing the average forecast of $21.47M by -41.49%. Lastly, the company's EPS was $-0.0007, missing the average prediction of $-0.153 by -99.54%